Redhill Biopharma's Opaganib For Medical Countermeasure For Gastrointestinal Acute Radiation Syndrome Has Been Awarded A Further $1.7M In US Government Funding, Via Small Business Innovation Research Grant To Its Partner, Apogee Biotechnology
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma's Opaganib, a medical countermeasure for gastrointestinal acute radiation syndrome, has been awarded an additional $1.7M in US government funding. The funding comes via a Small Business Innovation Research grant to its partner, Apogee Biotechnology.
July 21, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Redhill Biopharma's Opaganib has received an additional $1.7M in US government funding, which could potentially accelerate its development and commercialization.
The additional funding for Opaganib, a product of Redhill Biopharma, signifies increased support and confidence in the product's potential. This could lead to accelerated development and commercialization, which would likely have a positive impact on Redhill Biopharma's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100